MARSTACIMAB (Hympavzi®)

Clinical Indication

For treating severe haemophilia B in people 12 years and over without anti-factor antibodies

Comments

TA supports use in haemophilia B only

In line with NICE TA 1073

Date of classification

July 2025

Red

Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.